Bristol-Myers Squibb Co. (BMY) News

Bristol-Myers Squibb Co. (BMY): $74.83

-2.01 (-2.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BMY News Items

BMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BMY News Highlights

  • BMY's 30 day story count now stands at 81.
  • Over the past 21 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 17.
  • HCM, DRUG and MET are the most mentioned tickers in articles about BMY.

Latest BMY News From Around the Web

Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses.

Yahoo | February 25, 2022

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Yahoo | February 25, 2022

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

View more earnings on BHVNSee more from BenzingaBlood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study ShowsModerna Adds Three New mRNA-Based Development Programs To Its Pipeline© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | February 25, 2022

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...

PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent....

Yahoo | February 25, 2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...

PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-line Treatment of Patients with....

Yahoo | February 25, 2022

Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Taldefgrobep is the third development asset licensed to Biohaven from Bristol Myers Squibb and a clinical trial for Spinal Muscular Atrophy (SMA) is expected to begin in 2022.

Yahoo | February 25, 2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

PRINCETON, N.J., February 25, 2022--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected....

Yahoo | February 25, 2022

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Yahoo | February 24, 2022

10 Best Dividend Stocks to Buy According to Kahn Brothers

In this article, we discuss the 10 best dividend stocks to buy according to Kahn Brothers. You can skip our detailed analysis of the hedge fund’s investment philosophy, and go directly to read 5 Best Dividend Stocks to Buy According to Kahn Brothers. Kahn Brothers Group, an investment management firm, was founded by Irving Kahn, […]

Yahoo | February 24, 2022

Kim Schrier Stock Portfolio: 10 Stocks To Consider

In this article, we discuss the 10 stocks to consider in the portfolio of Kim Schrier. If you want to skip our detailed analysis of these stocks, go directly to Kim Schrier Stock Portfolio: 5 Stocks To Consider. Kim Schrier is a physician and politician born in California. She is presently a member of the […]

Yahoo | February 23, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6912 seconds.